Zobrazeno 1 - 6
of 6
pro vyhledávání: '"E. F. Klinushkina"'
Autor:
E. A. Dmitrieva, S. V. Voloshin, K. D. Kaplanov, V. Touliet, V. V. Zasypkina, O. V. Magdych, E. F. Klinushkina
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 79-91 (2024)
Background. Chronic lymphocytic leukemia (CLL) is a slowly progressive malignant disease that results in uncontrolled proliferation and accumulation of B-lymphocytes in the blood and bone marrow, and is the most common form of leukemia in Western cou
Externí odkaz:
https://doaj.org/article/f479661df1be4948a604e805204e6a72
Publikováno v:
Журнал микробиологии, эпидемиологии и иммунобиологии, Vol 1, Iss 1, Pp 100-104 (2019)
Аim. A study of CXCL12 effect on the migration of mononuclear cells isolated from healthy patients, from patients with myelomonoblastic leukemia before and after chemotherapy and the study of CCR4, EGFR and CXCL12 genes expression after exposure to
Externí odkaz:
https://doaj.org/article/d3fd5a31c5cd4b6785df34f15f0ca4c2
Autor:
K. A. Belousov, T. A. Mitina, Yu. Yu. Chuksina, A. K. Golenkov, E. V. Kataeva, E. V. Trifonova, Yu. B. Chernykh, L. L. Vysotskaya, S. G. Zakharov, E. F. Klinushkina, A. N. Mitin
Publikováno v:
Онкогематология, Vol 14, Iss 1, Pp 14-19 (2019)
Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (1
Externí odkaz:
https://doaj.org/article/9d44a6473ca940b5939c7131d1ff3f5b
Autor:
S. G. Zakharov, A. K. Golenkov, V. A. Misyurin, E. V. Kataeva, M. A. Baryshnikova, Yu. Yu. Chuksina, T. A. Mitina, E. V. Trifonova, L. L. Vysotskaya, Yu. B. Chernykh, E. F. Klinushkina, K. A. Belousov, Yu. P. Finashutina, A. V. Misyurin
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 46, Iss 8, Pp 734-741 (2018)
Background: We have previously shown that the FAS, TNFR2, TRAIL, DR3, DR4/5 gene expression in patients with newly diagnosed chronic lymphoblastic leukemia (CLL) correlates with clinical manifestations of the disease: they are minimal in patients wit
Externí odkaz:
https://doaj.org/article/5700002fb2d745459e510326b80d8937
Publikováno v:
Терапевтический архив, Vol 82, Iss 7, Pp 57-61 (2010)
Aim. To evaluate the effectiveness of bortezomib and bortezomib-containing treatment programs in the therapy of resistant and recurrent multiple myeloma (MM) within a large unicenter study in real clinical practice conditions. Subjects and methods. T
Externí odkaz:
https://doaj.org/article/a34873e0123a4b388baa16c96428a66b
Autor:
E. V. Trifonova, Yu. B. Chernykh, K. A. Belousov, S. G. Zakharov, E. V. Kataeva, E. F. Klinushkina, Yu. Yu. Chuksina, Anatoly Golenkov, A. V. Misyurin, Yu. P. Finashutina, V. A. Misyurin, L. L. Vysotskaya, M. A. Baryshnikova, T. A. Mitina
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 46, Iss 8, Pp 734-741 (2018)
Background: We have previously shown that the FAS, TNFR2, TRAIL, DR3, DR4/5 gene expression in patients with newly diagnosed chronic lymphoblastic leukemia (CLL) correlates with clinical manifestations of the disease: they are minimal in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ab0046e7c347fd4462fe17875039e18
https://www.almclinmed.ru/jour/article/view/933
https://www.almclinmed.ru/jour/article/view/933